DeepMed Research

Sintilimab

Generic Name: Sintilimab

Drug Type: Biotech

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Clinical Trials

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Sintilimab
Drug: IBI110
Drug: Paclitaxel
Drug: Cis Platinum
Procedure: Surgery
Radiation: Adjuvant radiation

First Posted Date: 2024-07-10

Last Posted Date: 2025-02-25

Lead Sponsor: Fudan University

Target Recruit Count: 27

Registration Number: NCT06494943

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Phase 2

Conditions: Gastric Cancer Peritoneal Metastases

Interventions: Drug: albumin-bound paclitaxel (260 mg/m2, d1)
Drug: S-1
Drug: sintilimab
Drug: bevacizumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 42

Registration Number: NCT06487715

Locations: 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Phase 3

Not yet recruiting

Conditions: Resectable Non-small Cell Lung Cancer

Interventions: Drug: sintilimab plus platinum-based chemotherapy

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 90

Registration Number: NCT06485557

Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

Conditions: Resectable Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sintilimab (PD-1 inhibitor)

First Posted Date: 2024-06-26

Last Posted Date: 2024-06-26

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 90

Registration Number: NCT06475196

Locations: 🇨🇳
Tangdu Hospital of the Fourth Millitary Medical University, Xi'an, Shaanxi, China

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06463834

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

Active, not recruiting

Conditions: HCC
Recurrence
Immunotherapy
Adjuvant Therapy

Interventions: Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Chen Xiaoping

Target Recruit Count: 620

Registration Number: NCT06461936

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, Hubei, China

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Not Applicable

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: Sintilimab
Drug: NAs
Drug: Peg-IFNα-2b

First Posted Date: 2024-06-13

Last Posted Date: 2024-06-20

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 50

Registration Number: NCT06457477

Locations: 🇨🇳
the Fifth Medical Center, Chinese PLA General Hospital, Beijing, Beijing, China

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Drug: Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel
Drug: Sintilimab + S-1 plus nab-paclitaxel

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 158

Registration Number: NCT06454435

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06447636

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1

Recruiting

Conditions: Leptomeningeal Metastasis
NSCLC
PD-1 Inhibitor
Low Dose Radiotherapy

Interventions: Radiation: Whole Brain Low Dose Radiotherapy
Drug: Pemetrexed
Drug: Sintilimab
Drug: Chemotherapy

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Sichuan University

Target Recruit Count: 10

Registration Number: NCT06431685

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy